Radiopharm Theranostics (ASX:RAD) Begins Phase 2b U.S. Trial for 18F-RAD101
Radiopharm Theranostics (ASX:RAD) initiates Phase 2b U.S. trial of 18F-RAD101, advancing diagnostic capabilities for brain metastasis.
Radiopharm Theranostics
Radiopharm Theranostics (ASX:RAD) initiates Phase 2b U.S. trial of 18F-RAD101, advancing diagnostic capabilities for brain metastasis.